Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFIRI + ramucirumab in early recurrent colorectal cancer after oxaliplatin/fluoropyrimidine adjuvant therapy (RAINCLOUD / RAINCLOUD-TR)
jRCTs051180238Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Sep 2017; status: completed.
02
Drugs
ramucirumabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051180238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180238.